Latest News

  • Arix leads $30m financing for Atox Bio

    04 December 2017 | Arix Bioscience
    Arix Bioscience has led an oversubscribed $30 million series F financing round for Atox Bio. Atox Bio is a late stage clinical biotechnology company developing novel immune modulators for...
  • Arix Bioscience non-exec to step down

    10 November 2017 | Arix Bioscience
    Arix Bioscience non-executive director Sir John Banham is retiring from the board. The company said: 'Sir John, who is 76, has been chairman of the audit and risk committee, and has helped to...
  • Arix Bioscience strengthens its board

    17 October 2017 | Arix Bioscience
    Arix Bioscience has appointed Giles Kerr as a non-executive director and chairman of the board's audit committee. Kerr has 36 years' experience in finance across a broad range of industrial...

More News

Broker Consensus (6 months)

Broker notes for Arix Bioscience (Data delayed by 3 months for free users)